Agenus Inc., 10% Owner at MiNK Therapeutics, Inc. (INKT), bought 379,051 shares at $1.08 ($399K) on 2023-05-03, disclosed to the SEC on 2023-05-05.
Open-market purchase of $399k INKT by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.08 | 128,689 | $139K | 34.8% |
| 2 | $1.08 | 128,689 | $139K | 34.8% |
| 3 | $1.22 | 21,473 | $26K | 6.6% |
| 4 | $0.95 | 100,000 | $95K | 23.8% |
| 5 | $1.25 | 200 | $250 | 0.1% |
| Total | $1.05 avg | 379,051 |
| $399K |
| 100% |
| Filing → |
| INKT | BUY | 2023-08-31 | $45K | — | Filing → |
| INKT | BUY | 2023-08-28 | $543K | — | Filing → |
| INKT | BUY | 2023-05-12 | $67K | — | Filing → |